|
🐜
|
Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
46 auth.
Chi-yi Chen,
Chung-Feng Huang,
P. Cheng,
K. Tseng,
Ching-chu Lo,
H. Kuo,
Yi‐Hsiang Huang,
C. Tai,
C. Peng,
Ming-Jong Bair,
Chien-Hung Chen,
M. Yeh,
Chih-Lang Lin,
Chun‐Yen Lin,
Pei‐Lun Lee,
...
L. Chong,
Chao-Hung Hung,
Jee‐Fu Huang,
Chi‐Chieh Yang,
Jui-Ting Hu,
Chih‐Wen Lin,
Chun‐Ting Chen,
Chia-Chi Wang,
W. Su,
T. Hsieh,
Chih‐Lin Lin,
W. Tsai,
Tzong‐Hsi Lee,
Guei-Ying Chen,
Szu-Jen Wang,
Chun-Chao Chang,
L. Mo,
Sheng-Shun Yang,
Wen-Chih Wu,
Huang Chia-Sheng,
Chou Hsiung,
Chien-Neng Kao,
P. Tsai,
Chen‐Hua Liu,
Mei‐Hsuan Lee,
Chun-Jen Liu,
C. Dai,
J. Kao,
W. Chuang,
Han‐Chieh Lin,
Ming‐Lung Yu
|
5 |
2021 |
5
🐜
|
|
🐜
|
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
49 auth.
P. Cheng,
L. Mo,
Chun‐Ting Chen,
Chi-yi Chen,
Chung-Feng Huang,
H. Kuo,
Ching-chu Lo,
K. Tseng,
Yi‐Hsiang Huang,
C. Tai,
C. Peng,
Ming-Jong Bair,
C.-H. Chen,
M. Yeh,
Chih-Lang Lin,
...
Chun‐Yen Lin,
Pei‐Lun Lee,
L. Chong,
Chao-Hung Hung,
T. Chang,
Jee‐Fu Huang,
Chi‐Chieh Yang,
Jui-Ting Hu,
Chih‐Wen Lin,
Chia-Chi Wang,
W. Su,
T. Hsieh,
Chih‐Lin Lin,
W. Tsai,
Tzong‐Hsi Lee,
Guei-Ying Chen,
Szu-Jen Wang,
Chun-Chao Chang,
Sheng-Shun Yang,
Wen-Chih Wu,
Chia-Sheng Huang,
K. Chou,
Chien-Neng Kao,
P. Tsai,
Chen‐Hua Liu,
Mei‐Hsuan Lee,
Chien-Yu Cheng,
M. Tsai,
Chun-Jen Liu,
C. Dai,
Han‐Chieh Lin,
J. Kao,
W. Chuang,
Ming‐Lung Yu
|
4 |
2021 |
4
🐜
|
|
🐜
|
Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV Registry Program (TACR).
48 auth.
Chung-Feng Huang,
K. Tseng,
P. Cheng,
Chao-Hung Hung,
Ching-chu Lo,
C. Peng,
Ming-Jong Bair,
M. Yeh,
Chien-Hung Chen,
Pei‐Lun Lee,
Chun‐Yen Lin,
H. Kuo,
Chun‐Ting Chen,
Chi‐Chieh Yang,
Jee‐Fu Huang,
...
C. Tai,
Jui-Ting Hu,
Chih-Lang Lin,
W. Su,
W. Tsai,
Yi‐Hsiang Huang,
Chien-Yu Cheng,
Chih‐Lin Lin,
Chia-Chi Wang,
Sheng-Shun Yang,
L. Mo,
Guei-Ying Chen,
Chun-Chao Chang,
Szu-Jen Wang,
Chia-Sheng Huang,
T. Hsieh,
Chih‐Wen Lin,
Tzong‐Hsi Lee,
L. Chong,
Chien-Wei Huang,
Shiuh‐Nan Chang,
M. Tsai,
Shih-Jer Hsu,
J. Kao,
Chun-Jen Liu,
Chen‐Hua Liu,
Han‐Chieh Lin,
Mei‐Hsuan Lee,
P. Tsai,
C. Dai,
W. Chuang,
Chi-yi Chen,
Ming‐Lung Yu
|
4 |
2021 |
4
🐜
|
|
🐜
|
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
43 auth.
Chung-Feng Huang,
H. Kuo,
Te-Sheng Chang,
Ching-chu Lo,
Chao-Hung Hung,
Chien-Wei Huang,
L. Chong,
P. Cheng,
M. Yeh,
C. Peng,
Chien-Yu Cheng,
Jee‐Fu Huang,
Ming-Jong Bair,
Chih-Lang Lin,
Chi‐Chieh Yang,
...
Szu-Jen Wang,
T. Hsieh,
Tzong‐Hsi Lee,
Pei‐Lun Lee,
Wen-Chih Wu,
Chih‐Lin Lin,
W. Su,
Sheng-Shun Yang,
Chia-Chi Wang,
Jui-Ting Hu,
L. Mo,
Chun‐Ting Chen,
Yi‐Hsiang Huang,
Chun-Chao Chang,
Chia-Sheng Huang,
Guei-Ying Chen,
Chien-Neng Kao,
C. Tai,
Chun-Jen Liu,
Mei‐Hsuan Lee,
P. Tsai,
C. Dai,
J. Kao,
Han‐Chieh Lin,
W. Chuang,
Chi-yi Chen,
K. Tseng,
Ming‐Lung Yu
|
3 |
2021 |
3
🐜
|
|
🦁
|
A Bioinformatics Analysis Identifies the Telomerase Inhibitor MST-312 for Treating High-STMN1-Expressing Hepatocellular Carcinoma
Szu-Jen Wang,
Pei-Ming Yang
|
3 |
2021 |
3
🦁
|
|
🐜
|
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
43 auth.
T. Chang,
Chung-Feng Huang,
H. Kuo,
Ching-chu Lo,
Chien-Wei Huang,
L. Chong,
P. Cheng,
M. Yeh,
C. Peng,
Chien-Yu Cheng,
Jee‐Fu Huang,
Ming-Jong Bair,
Chih-Lang Lin,
Chi‐Chieh Yang,
Szu-Jen Wang,
...
T. Hsieh,
Tzong‐Hsi Lee,
Pei‐Lun Lee,
Wen-Chih Wu,
Chih‐Lin Lin,
W. Su,
Sheng-Shun Yang,
Chia-Chi Wang,
Jui-Ting Hu,
L. Mo,
Chun‐Ting Chen,
Yi‐Hsiang Huang,
Chun-Chao Chang,
Chia-Sheng Huang,
Guei-Ying Chen,
Chien-Neng Kao,
C. Tai,
Chun-Jen Liu,
Mei-Hsuan Lee,
P. Tsai,
C. Dai,
J. Kao,
Han‐Chieh Lin,
W. Chuang,
Chi-yi Chen,
K. Tseng,
Chao-Hung Hung,
Ming‐Lung Yu
|
3 |
2023 |
3
🐜
|
